Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial
Heikki Joensuu(Orion Corporation (Finland)), Henrik Lindman(Uppsala University), Leena Helle(Kotka Maritime Research Centre), R. Kokko, Paula Poikonen‐Saksela(Turku University Hospital), Arja Jukkola‐Vuorinen(University of Oulu), Päivi Auvinen(University of Eastern Finland), Minna Tanner(Tampere University Hospital), Paul Nyandoto(Päijät-Hämeen Keskussairaala), Johan Ahlgren(Uppsala University), Vesa Kataja(Kuopio University Hospital), Outi Paija(Turku University Hospital), Riikka Huovinen(Turku University Hospital), Akseli Hemminki(University of Helsinki), Lauri Nuortio(North Karelia Central Hospital), Sirpa-Liisa Lahtela(Helsinki University Hospital), R. Asola(Satakunta Central Hospital), Marjo Pajunen(Central Finland Health Care District), Greger Nilsson(Turku University Hospital), Pirkko‐Liisa Kellokumpu‐Lehtinen, Kenneth Villman(Örebro University Hospital), Petri Bono(Helsinki University Hospital), Mika Leinonen, Kaisa Lehtiö(Helsinki University Hospital)
Cited by 65
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k